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Abstract: The occurrence of peroxisome proliferator-activated receptors gamma (PPARγ) was investigated in 51 human
pituitary adenomas and in 6 non-tumoral human pituitary tissue samples. Moreover, the correlation between PPARγ and the
proliferating cells nuclear antigen (PCNA) - immunocytochemical proliferation marker was evaluated. The receptors and
PCNA were detected by immunohistochemical methods using the polyclonal anti-PPARγ and the monoclonal anti-PCNA
antibodies, respectively. PPARγ were found in all examined tissues. The mean percentage of cells with positive nuclear reaction
was 3-fold higher in pituitary adenomas in comparison with non-tumoral pituitary tissues. The strongest expression of PPARγ
was observed in somatotropinomas. Besides the nuclear reaction, which is typical for PPARγ, positive immunostaining was
also observed in the cytoplasm. It was clearly stronger in pituitary adenomas than in non-tumoral pituitary tissues. A slight,
statistically insignificant tendency towards negative correlation between PPARγ and PCNA was found in somatotropinomas,
prolactinomas, corticotropinomas and gonadotropinomas. On the other hand, in null cell adenomas and "silent" corticotropi-
nomas, a strong positve correlation between the expression of PPARγ and PCNA was observed. The strong expression of
PPARγ in human pituitary adenomas and its possible involvement in control of cell proliferation in these tumors give a good
reason for the attempts of their treatment with PPARγ ligands.
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Introduction
The peroxisome proliferator-activated receptors gamma
(PPARγ) are nuclear receptors involved in many physi-
ological and pathological processes including glucose
and lipid metabolism, atherosclerosis, inflammation and
carcinogenesis [14]. PPARγ forms a heterodimer with
retinoid X receptor (RXR) and regulates expression of
target genes by binding to the PPARγ responsive ele-
ment [16]. Polyunsaturated fatty acids and prostaglandin
metabolite 15-deoxy-Δ12,14-prostaglandin J2 have been
identified as endogenous ligands for PPARγ [9, 17]. It
was shown that thiazolidinediones (TZD) used as insulin
sensitizers in type 2 diabetes and some nonsteroidal
antiinflamatory drugs are high affinity synthetic PPARγ
ligands [21, 22]. The highest levels of PPARγ are de-
tected in adipocytes, but these receptors are also widely
expressed in other normal cells and tissues such as
monocytes, liver, skeletal muscle and neoplasmatic cells
[8, 19]. It was proven in experimental investigations that
activation of PPARγ receptors inhibits growth of many
types of tumors [19]. The mechanism by which PPARγ
ligands exert their oncostatic effects is very complex and
still not clear. Several studies have proved that TZD
(troglitazon, pioglitazon and rosiglitazon) can inhibit
proliferation and induce apoptosis of cancer cells [19].
Moreover, in liposarcoma and breast, colon and prostate
cancers, the synthetic PPARγ ligands cause the terminal
differentiation [6, 15, 23, 24]. Recent studies have indi-
cated that PPARγ are expressed in the endothelium of
tumoral vessels and that TZD suppress tumor growth
also via antiangiogenic action [26]. 
 It was also shown that PPARγ agonists inhibited the
in vitro growth of experimental and spontaneous pitui-
tary adenomas and in vivo growth of experimental ani-
mal pituitary tumors [11, 12]. The antitumoral effects of
these compounds seem to depend on the presence of
PPARγ in tumor cells. In pituitary adenomas, the over-
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expression of PPARγ was found as compared with nor-
mal tissues [12].
The aim of our study was to estimate the occurrence
of PPARγ in the human pituitary adenomas and in the
non-tumoral human pituitary gland. Since the prolif-
erating cells nuclear antigen (PCNA) is a good marker
for immunohistochemical assessment of cell prolifera-
tion in pituitary adenomas [18], we examined the corre-
lation between PPARγ and PCNA.
Materials and methods
Human pituitary adenomas. Fifty one surgically removed pituitary
adenomas were investigated. The tumors were fixed in Bouin-Hol-
lande fixative and embedded in paraffin. Histological and immunoh-
istochemical diagnoses were performed using the Herlant’s
tetrachome staining and immunostaining with antisera against the
pituitary hormones and their subunits, respectively. The following
pituitary adenomas were included into present study: 11 somatotropi-
nomas, 8 prolactinomas, 6 corticotropinomas (Cushing disease), 5
"silent" corticotropinomas (lack of clinical symptoms of hypercorti-
cism), 14 gonadotropinomas and 7 null cell adenomas (tumors
immunonegative for all the investigated pituitary hormones and their
subunits). Moreover, 6 non-tumoral pituitary tissue samples (ad-
jacent to removed microadenomas) were studied.
PPARγ and PCNA immunostaining. The paraffin sections (4 μm)
were immunostained with polyclonal anti-PPARγ antibody (Cal-
biochem, La Jolla, California, USA) and monoclonal anti-PCNA
antibody (Dako Cytomation, Denmark). Both antibodies were used
at 1:1000 dilution. The binding of anti-PPARγ antibody was detected
using anti-rabbit IgG biotinylated goat antibody, streptavidin com-
plex (StreptABC Complex/HRP, Dako) and 3,3’-diaminobenzidine.
Detection of anti-PCNA antibody was performed using DakoCyto-
mation Envision System, AP (Fast Red). The kit includes levamisole
as an inhibitor of endogenous alkaline phosphatase and a Fast Red
chromogenic substrate system. Finally, the sections were counter-
stained with hematoxylin. A negative control was obtained by omit-
ting the incubation with primary antibodies. Under × 1000
magnification, the number of cell with immunopositive nuclear
reaction was counted among 1000 randomly chosen tumor or pitui-
tary cells.
Statistical analysis. The correlation between PPARγ and PCNA was
analysed by the Pearsons correlation coefficient. Statistical signific-
ance was set at P<0.05.
Results
The occurrence of PPARγ was demonstrated in all the
examined tissues (Figs. 1, 2). Besides the nuclear reac-
tion, which is typical for PPARγ, positive immunostain-
ing was also observed in the cytoplasm (Fig. 3) and in
case of non-tumoral pituitary tissues also in the stroma
(Fig. 1). The latter staining seems to be unspecific. Three
types of PPARγ localization were noticed: in the nuclear
region, in the cytoplasm and in both nucleus and cyto-
plasm. The mean percentage of the PPARγ-immuno-
positive cell nuclei in human pituitary adenomas and in
non-tumoral pituitary tissues are shown in Figure 4. The
strongest expression of PPARγ was observed in soma-
totropinomas. A relatively high number of immunoposi-
tive cell nuclei was found in prolactinomas. The mean
percentage of cells with positive nuclear reaction was
3-fold higher in pituitary adenomas (mean 126‰) in
comparison with non-tumoral pituitary tissues (mean
41‰). The cytoplasmic expression of PPARγ was also
stronger in pituitary adenomas than in non-tumoral tis-
sues (data not shown). Estimating the relationship be-
tween PPARγ and PCNA, a slight, statistically insigni-
ficant tendency towards negative correlation between
PPARγ and PCNA was found in somatotropinomas,
prolactinomas, corticotropinomas and gonado- tropino-
mas (Fig. 5). On the other hand, in null cell adenomas
and "silent" corticotropinomas, a strong positve correla-
tion (statistically significant) was observed between the
expression of PPARγ and PCNA (Fig. 6). 
Discussion
Our finding of increased expression of PPARγ in pitui-
tary adenomas as compared to non-tumoral pituitary
tissue is an agreement with the earlier observation of
Haeney et al. [12]. This finding is also compatible with
data showing the enhanced expression of PPARγ in
several cancers such as: breast cancer [7], colon cancer
[5], testicular cancer [13], glioblastoma [30], urinary
bladder cancer [29] and differentiated thyroid cancers
[10]. However, in some other cancers the expression of
PPARγ is lower than in the corresponding normal tis-
sues, e.g. in esophageal cancer [28] and choriocarcino-
ma [4]. Since PPARγ are nuclear receptors, their
immunodetection within the nuclei was expected. The
immunostaining in the cytoplasmic region observed in
some cells is more difficult to explain. Such immunos-
taining was also observed in some other tumors like
esophageal cancer and non-small lung cancer [28, 20].
Moreover, in salivary duct cancer only cytoplasmic
PPARγ immunopositivity was detected [25]. Although
the significance of the cytoplasmic PPARγ overexpress-
ion remains unknown, it might be speculated that it
results from the retention of receptor protein in the
cytoplasm. Such a retention could diminish or even
make impossible the proper biological action of the
receptors within the cell nucleus. Summing up, these
findings indicate a role of PPARγ in oncogenesis includ-
ing pituitary tumorigenesis. 
Since PCNA immunoreactivity was shown as a mar-
ker of proliferative activity and aggressiveness of pitui-
tary adenomas [2, 27], we estimated the relationship of
PPARγ and PCNA in the investigated tumors. The ob-
served tendency towards the negative correlation in
pituitary adenomas with exception of null cell adenomas
and "silent" corticotropinomas suggests the involvement
of PPARγ in the control of cell proliferation in these
tumors. On the other hand, a strong positive correlation
between PPARγ and PCNA in null cell adenomas and
"silent" corticotropinomas indicate that this involvement
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Fig. 1. The human non-tumoral pituitary tissue immunos-
tained with anti-PPARγ antibody, showing a positive reac-
tion (brown) in a few nuclei of glandular cells. The
unspecific brown coloration can be seen also in the stroma.
× 400.
Fig. 3. The human prolactinoma immunostained with anti-
PPARγ antibody, showing immunopositive reaction in cy-
toplasm of tumoral cells besides the nuclear reaction. × 400.
Fig. 2. The human somatotropinoma immunostained with
anti-PPARγ antibody, showing a strong nuclear reaction in
the tumor cells. × 400.
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may be opposite in different pituitary adenoma types.
The strong expression of PPARγ in human pituitary
adenomas and its possible involvement in control of cell
proliferation in these tumors justify the attempts of
treatment of pituitary tumors with PPARγ ligands.
Such attempts were already made in patients with Cush-
ing disease [3, 1]. It remains to establish in further
studies whether the high expression of PPARγ can pre-
dict the positive effect of TZD treatment of pituitary
tumors. 
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